News Rumour mill has Camurus buying partner Braeburn Camurus is said to be in talks to acquire US partner Braeburn in a deal that would give it control of their product for treating opioid use disorder.
News FDA to reconsider Braeburn's opioid addiction drug after cou... A US district court has ruled that the FDA must reconsider its decision to reject a long-lasting opioid addiction treatment drug from Braeburn, overthrowing a ruling granting exclusivity to
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.